List of Beleodaq drug patents

Beleodaq is owned by Acrotech.

Beleodaq contains Belinostat.

Beleodaq has a total of 2 drug patents out of which 0 drug patents have expired.

Beleodaq was authorised for market use on 03 July, 2014.

Beleodaq is available in powder;intravenous dosage forms.

Beleodaq can be used as treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl)..

The generics of Beleodaq are possible to be released after 27 October, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6888027 ACROTECH Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(4 years from now)

Drugs and Companies using BELINOSTAT ingredient

Market Authorisation Date: 03 July, 2014

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic